146
Participants
Start Date
June 21, 2017
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Cemiplimab
Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
Ipilimumab
To be administered per protocol
Platinum-doublet chemotherapy
To be administered per protocol
Gemcitabine
To be administered per protocol
Pemetrexed
To be administered per protocol
Paclitaxel
To be administered per protocol
Fianlimab
To be administered per protocol
National Hospital Organization Nagoya Medical Center, Nagoya
Kurume University Hospital, Kurume
Gunma Prefectural Cancer Center, Ōta
Kobe City Medical Center General Hospital, Kobe
Kanazawa University Hospital, Kanazawa
Kitasato University Hospital, Sagamihara
Kanagawa Cardiovascular and Respiratory Center, Yokohama
Kanagawa Cancer Center - Thora, Yokohama
Sasebo City General Hospital, Sasebo
Kurashiki Central Hospital, Kurashiki
Kansai Medical University Hirakata Hospital, Hirakata
Osaka Metropolitan University Hospital, Osaka
National Hospital Organization Kinki-chuo Chest Medical Center, Sakai-shi
Osaka Medical and Pharmaceutical University Hospital, Takatsuki
Saitama Cancer Center, Shinden
National Cancer Center Hospital - Tsukiji Campus, Chuo Ku
Hiroshima City Hiroshima Citiz, Hiroshima
Nagasaki University Hospital, Nagasaki
Osaka International Cancer Institute, Osaka
Tokushima University Hospital, Tokushima
Regeneron Pharmaceuticals
INDUSTRY